The development of a medicine for patients with type 1 diabetes mellitus, based on autoantigen GAD65, received a setback following crucial clinical phase 3 trials that failed to show significant effects. One possible explanation may be seasonal variations in the immune system, claim those responsible for the study that was published in the New England Journal of Medicine (NEJM).
“We have not given up, rather we still believe that the GAD-alum may prove to be an important part of both prevention and treatment of type 1 diabetes,” says Johnny Ludvigsson, Professor emeritus in Paediatrics at LiU (Linköpings universitet).
Read the full article here